Skip to main content

Infection

#TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/h0oe3WksK1
Dr. John Cush @RheumNow( View Tweet )

Generic Tofacitinib (6.26.2026)

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

Read Article
Do You Zoster Vaccinate? (6.19.2026) Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026. https://t.co/hOfXR39s3H https://t.co/X7skwKrCc3
Dr. John Cush @RheumNow( View Tweet )
Systematic review of live virus MMR in #JIA had 9 studies (743 pts) showing no flares, good safety & immunogenicity in short term, BUT incomplete or less durable protection in biologic-treated patients, especially for measles & rubella. 5-yrs post MMR, seroprotection was lower if https://t.co/JQhL9o1O4e
Dr. John Cush @RheumNow( View Tweet )
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/7HUqGGBeJ8
Dr. John Cush @RheumNow( View Tweet )

Do You Zoster Vaccinate? (6.19.2026)

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

Read Article

EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases

This update includes new pandemic era evidence, recombinant zoster vaccine data, and new perspectives on vaccination in patients taking novel immunosuppressants. Five overarching principles and 10 vaccine recommendations follow.

Read Article
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/j2jrBIiuOo
Dr. John Cush @RheumNow( View Tweet )

EULAR 2026 Rheumatology RoundUp

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
A bridge to uncertainty? large #RCT of #baricitinib V #TNFi In Active #RA w #DVT/#VTE risk factor(s) Sl more VTE, #infection #SIE on #Bar NO increase #MACE Sl ⬆️#malignancy #VTE rate exceeded upper limit of a priori #CI So is this good news or not? #LB0009 @RheumNow #EULAR2026 https://t.co/CIfU7TL2TE
Janet Pope @Janetbirdope( View Tweet )
#EULAR2026 #SARD #vaccination #recommendations I think 🤔 ✅proactive➡️take responsibility ✅close gap ✅mostly practical But How long will #shingrix work if #vaccine In age<50yrs When if ever To revaccinate? @RheumNow @eular_org @ACRheum https://t.co/najJwzdecL
Janet Pope @Janetbirdope( View Tweet )
TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190 https://t.co/4yjD9CmySM
Dr. John Cush @RheumNow( View Tweet )
#EULAR2026 Recommendations: Immunization (new since 2011) - Vaccinate early regardless of dz acitiviry - HBV booster/passive if poor response - Yellow fever may be considered on individual basis - Avoid live vaccines (mostly) in newborn exposed in utero to biologic @RheumNow

Jiha Lee @JihaRheum( View Tweet )

#EULAR2026 #vaccination #guidelines ➡️be proactive ❎disease activity doesn’t matter ✅it is responsibility of #rheumatologist to discuss and update pt? @RheumNow @eular_org https://t.co/dRnHd9CThg
Janet Pope @Janetbirdope( View Tweet )
How to treat #RA-#ILD Similar to #IPF Occurs older men esp Smoking risk Vaccines Etc Philippe Dieude #HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF
Janet Pope @Janetbirdope( View Tweet )
Controversial #Rheumatoid #arthritis disease activity May not affect #ILD BUT affects #mortality level evidence +/- PHillippe Dieude said #Rx from RCTs #IS Ex #rituximab #antifibrotics #nintedanib #nerandomilast HOw to Treat RA-ILD June 5 #EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8
Janet Pope @Janetbirdope( View Tweet )
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated. Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067

Bella Mehta @bella_mehta( View Tweet )

Interesting poster #POS0939 from @SteZhao #EULAR2026 Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals 11,611 HLA-B27+ UK biobank Recall bias? Yes but self-reported exposure validated with primary care data @RheumNow https://t.co/VmxI3BW6FE
Nelly ZIADE 🍀 @Nellziade( View Tweet )
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up. Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
True or False: After successfully treating herpes zoster, it is considered safe to restart anti-TNF therapy without a significant risk of recurrence. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/pGggdVPhmh
Dr. John Cush @RheumNow( View Tweet )
Veterans Administration study of 301 #RA pts Rx w/ immune checkpoint inhibitor (ICI) for cancer shows all cause mortality in ICI Rx Cancer pts was no worse when RA pts took ICIs (1.09; 0.94–1.25). Cause of death similar; Infx were rare (<1.0%) https://t.co/3ZYujU5nyE https://t.co/MCDcdWHcVx
Dr. John Cush @RheumNow( View Tweet )
×